IL184932A0 - Glucagon receptor antagonists, preperation and therapeutic uses - Google Patents

Glucagon receptor antagonists, preperation and therapeutic uses

Info

Publication number
IL184932A0
IL184932A0 IL184932A IL18493207A IL184932A0 IL 184932 A0 IL184932 A0 IL 184932A0 IL 184932 A IL184932 A IL 184932A IL 18493207 A IL18493207 A IL 18493207A IL 184932 A0 IL184932 A0 IL 184932A0
Authority
IL
Israel
Prior art keywords
compounds
glucagon receptor
preperation
methods
receptor antagonists
Prior art date
Application number
IL184932A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL184932(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL184932A0 publication Critical patent/IL184932A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL184932A 2005-02-11 2007-07-30 Glucagon receptor antagonists, preperation and therapeutic uses IL184932A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11
PCT/US2006/004461 WO2006086488A2 (en) 2005-02-11 2006-02-09 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
IL184932A0 true IL184932A0 (en) 2007-12-03

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL184932A IL184932A0 (en) 2005-02-11 2007-07-30 Glucagon receptor antagonists, preperation and therapeutic uses

Country Status (25)

Country Link
US (1) US8084489B2 (enExample)
EP (1) EP1856090B1 (enExample)
JP (1) JP4988604B2 (enExample)
KR (1) KR20070104409A (enExample)
CN (1) CN101115735B (enExample)
AT (1) ATE445609T1 (enExample)
AU (1) AU2006213894B2 (enExample)
BR (1) BRPI0607015A2 (enExample)
CA (1) CA2597073C (enExample)
CR (1) CR9304A (enExample)
CY (1) CY1109624T1 (enExample)
DE (1) DE602006009773D1 (enExample)
DK (1) DK1856090T3 (enExample)
EA (1) EA200701705A1 (enExample)
ES (1) ES2332470T3 (enExample)
IL (1) IL184932A0 (enExample)
MA (1) MA29432B1 (enExample)
MX (1) MX2007009661A (enExample)
NO (1) NO20074567L (enExample)
PL (1) PL1856090T3 (enExample)
PT (1) PT1856090E (enExample)
SI (1) SI1856090T1 (enExample)
TN (1) TNSN07313A1 (enExample)
WO (1) WO2006086488A2 (enExample)
ZA (1) ZA200706354B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1758853T1 (sl) * 2004-06-14 2010-05-31 Lilly Co Eli Antagonisti glukagonskega receptorja priprava inuporaba v terapiji
EP2786985B1 (en) 2007-02-09 2018-11-28 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
RU2013127611A (ru) 2010-12-23 2015-01-27 Пфайзер Инк. Модуляторы глюкагонового рецептора
MX2013009140A (es) 2011-02-08 2013-10-01 Pfizer Moduladores del receptor de glucagon.
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US10829519B2 (en) 2015-09-18 2020-11-10 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
DK3359209T4 (en) 2015-10-05 2025-06-30 Embios Gmbh Compositions and methods for treatment of bone defects
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
KR102708864B1 (ko) 2016-08-30 2024-09-25 리제너론 파마슈티칼스 인코포레이티드 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US12139546B2 (en) 2017-08-22 2024-11-12 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
TW202003453A (zh) 2018-02-13 2020-01-16 美商利根德製藥公司 升糖素受體拮抗劑
MX2022007665A (es) 2019-12-20 2022-07-19 Bayer Ag Tiofenocarboxamidas sustituidas y sus derivados.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463715A1 (en) * 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
EP1758859B1 (en) 2004-05-28 2013-07-17 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
SI1758853T1 (sl) 2004-06-14 2010-05-31 Lilly Co Eli Antagonisti glukagonskega receptorja priprava inuporaba v terapiji

Also Published As

Publication number Publication date
EP1856090A2 (en) 2007-11-21
PL1856090T3 (pl) 2010-02-26
JP4988604B2 (ja) 2012-08-01
CA2597073C (en) 2014-11-25
PT1856090E (pt) 2009-11-18
CY1109624T1 (el) 2014-08-13
SI1856090T1 (sl) 2010-02-26
EP1856090B1 (en) 2009-10-14
AU2006213894B2 (en) 2011-12-08
US8084489B2 (en) 2011-12-27
US20100137417A1 (en) 2010-06-03
ATE445609T1 (de) 2009-10-15
ES2332470T3 (es) 2010-02-05
ZA200706354B (en) 2008-11-26
CA2597073A1 (en) 2006-08-17
MA29432B1 (fr) 2008-05-02
CN101115735B (zh) 2013-01-09
CR9304A (es) 2008-03-31
JP2008530102A (ja) 2008-08-07
BRPI0607015A2 (pt) 2009-12-01
DK1856090T3 (da) 2009-11-30
NO20074567L (no) 2007-11-08
CN101115735A (zh) 2008-01-30
WO2006086488A3 (en) 2006-12-14
WO2006086488A2 (en) 2006-08-17
KR20070104409A (ko) 2007-10-25
MX2007009661A (es) 2007-09-25
AU2006213894A1 (en) 2006-08-17
DE602006009773D1 (de) 2009-11-26
TNSN07313A1 (en) 2008-12-31
EA200701705A1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
SI1861360T1 (sl) Derivati pirolidina kot antagonisti histaminskega h3 receptorja